The Investor
11 Nov 2026, 18:41
Zoetis Wins USDA License for 75-Day Cytopoint Plus Allergy Treatment for Dogs
Zoetis (NYSE: ZTS) received a U.S. Department of Agriculture license for Cytopoint Plus, a next-generation monoclonal antibody designed to provide 75 days of allergic itch relief in dogs with allergic dermatitis.
The treatment has the longest dosing interval among currently licensed monoclonal antibodies for canine allergic dermatitis. Cytopoint Plus is administered by a veterinarian as a single subcutaneous injection every 75 days, or about 10.7 weeks, potentially reducing the frequency of clinic visits and missed treatments.
Cytopoint Plus works by targeting and neutralizing interleukin-31, or IL-31, a protein involved in transmitting itch signals in dogs. Zoetis said the treatment begins relieving allergic itch within one day and maintains efficacy for 75 days.
The product expands Zoetis’ existing canine dermatology franchise, which already includes Cytopoint and Apoquel. Standard Cytopoint generally provides four to eight weeks of relief, while Cytopoint Plus extends the treatment interval to approximately 75 days.
In studies supporting the license, Cytopoint Plus demonstrated efficacy through Day 75 and had a safety profile similar to Cytopoint, with reduced itch scores versus controls observed through Day 90 in some dogs.
The approval strengthens Zoetis’ position in canine dermatology by adding a longer-acting option to a portfolio spanning injectable biologics and oral therapies, while addressing treatment adherence and convenience for both veterinarians and pet owners.
Zoetis (NYSE: ZTS) received a U.S. Department of Agriculture license for Cytopoint Plus, a next-generation monoclonal antibody designed to provide 75 days of allergic itch relief in dogs with allergic dermatitis.
The treatment has the longest dosing interval among currently licensed monoclonal antibodies for canine allergic dermatitis. Cytopoint Plus is administered by a veterinarian as a single subcutaneous injection every 75 days, or about 10.7 weeks, potentially reducing the frequency of clinic visits and missed treatments.
Cytopoint Plus works by targeting and neutralizing interleukin-31, or IL-31, a protein involved in transmitting itch signals in dogs. Zoetis said the treatment begins relieving allergic itch within one day and maintains efficacy for 75 days.
The product expands Zoetis’ existing canine dermatology franchise, which already includes Cytopoint and Apoquel. Standard Cytopoint generally provides four to eight weeks of relief, while Cytopoint Plus extends the treatment interval to approximately 75 days.
In studies supporting the license, Cytopoint Plus demonstrated efficacy through Day 75 and had a safety profile similar to Cytopoint, with reduced itch scores versus controls observed through Day 90 in some dogs.
The approval strengthens Zoetis’ position in canine dermatology by adding a longer-acting option to a portfolio spanning injectable biologics and oral therapies, while addressing treatment adherence and convenience for both veterinarians and pet owners.